Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Vitro Diagnostic Industry’s Political Playbook Rewritten As Firms Lobby On COVID-19 Legislation

Diagnostic companies spent tens of thousands of dollars to influence outcome of coronavirus bills in February, March

Executive Summary

Test kit and lab firms spent tens of thousands of dollars in the first quarter of 2020 lobbying legislators to win provisions in coronavirus protection laws to ensure COVID-19 diagnostics would be a top US legislative priority.

You may also be interested in...

Precision Medicine Bill Sponsored By Democrat Eric Swalwell Gains Support In US House

A bill that would promote genetic testing for infants and children, introduced by California Rep. Eric Swallwell, is gaining support in the US House of Representatives.

Clinical Lab Group Gets Go-Ahead On Medicare Payment Suit

The American Clinical Laboratory Association (ACLA) may proceed with a lawsuit against the US Department of Health and Human Services, an appeals court has ruled. The suit alleges that the agency is setting lab test payment rates unfairly.

ACLA Rejects FDA As A ‘Clinical Validity’ Judge, While AdvaMedDx Seeks Tweaks To VALID Act

Clinical labs are troubled by the idea of granting US FDA vast discretion to determine if laboratory-developed tests (LDTs) are analytically and clinically valid, a key feature of the draft US VALID Act, while in vitro diagnostic kit manufacturers want some clarifications and more flexibility written into the proposal for diagnostic regulatory reforms.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts